Purpose: Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2–directed antibody drug conjugate with a hydrolysable linker and a potent SN-38 payload. This study explored Trop-2 expression in tumors treated with SG in cohorts 1 to 3 (C1–3) from the TROPHY-U-01 study and evaluated whether efficacy was associated with Trop-2 expression. Patients and Methods: TROPHY-U-01 (NCT03547973) is an open-label phase II study that assessed the efficacy and safety of SG (alone or in combinations) in patients with unresectable locally advanced or metastatic UC (mUC). Archival tumor samples collected at enrollment for C1–3 were analyzed for Trop-2 membrane expression by considering histological scores (H-scores; scale 0–300) and the percentage of membrane positive tumor cells at low magnification (4×). The association of Trop-2 with clinical endpoints [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS)] was evaluated. Results: In C1–3, tissue was collected from 158 (82%) of 192 treated patients, and 146 (76%) had evaluable Trop-2 data. Trop-2 was highly expressed in tumor samples. The median [interquartile range (IQR)] Trop-2 H-score was 215 (180–246), and the median (IQR) percentage of membrane positive tumor cells was 91% (80–98). Trop-2 expression at any level was observed in 98% of patients. Furthermore, ORR, PFS, and OS benefits were observed across all Trop-2 expression levels. Conclusions: Trop-2 protein is highly expressed in UC, as confirmed by examining tumors from patients enrolled in the TROPHY-U-01 trial. The results indicate that SG demonstrates efficacy in mUC across Trop-2 expression levels.
1589 Background: Data still remain scanty on the potential impact of renal insufficiency (RI) on the mortality of cancer patients. The results of 3 clinical studies we conducted (IRMA-2, CANDY and MARS) were pooled. In all 3, methodology and investigators were the same regarding RI. Pooled analysis was thus allowed to study the potential association between RI and overall survival (OS), and to stratify the risk, if any, depending on the GFR Methods: The KDIGO definition and classification of CKD was used. GFR was estimated with the MDRD formula. RI was defined as GFR<60 ml/min/1.73 m². Results: Population included 5908 solid tumor patients (2181 breast, 854 colorectal, 556 lung, 366 ovarian, 293 prostate for the main tumors). Median age 59.2, mean BMI 24.4, 64.0% were women. 70.7% of these patients were alive at the end of the follow-up period of one year. Univariate analysis reported that RI was strongly linked to mortality (p < 0.0001), when analysing together all types of patients and tumors. Furthermo...